
Doravirine(cas:1338225-97-0)Doravirine (mk-1439) is a novel oral NNRTI-class HIV-1 reverse transcriptase inhibitor developed by MSD, which was first launched in Japan on March 6, 2026. It is administered once daily with a high genetic barrier to drug resistance and favorable safety profile, and is indicated for the combination therapy of HIV-1 infection in adults.
×